================================================================================
QUICK PATIENT-STUDY MATCHING REPORT
================================================================================
Generated: 2025-07-17 11:23:32
Total patients: 5

PATIENT 1
----------------------------------------
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
01/2017 V.a. neue Lebermetastase
02/2017 Start Somatoline
02/2018 CT Abdomen: stable disease
03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. 
Relevant studies found: 10

  1. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 55 - NET condition match; Small intestine NET match; Liver metastases match; Completed PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  2. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
     NCT ID: NCT01524783
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 50 - NET condition match; Small intestine NET match; Completed PHASE3 study; 5 publications
     URL: https://clinicaltrials.gov/study/NCT01524783

  3. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
     NCT ID: NCT01578239
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 47 - NET condition match; Small intestine NET match; Completed PHASE3 study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT01578239

  4. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
     NCT ID: NCT00171873
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 44 - NET condition match; Small intestine NET match; Completed PHASE3 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00171873

  5. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
     NCT ID: NCT00427349
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 44 - NET condition match; Small intestine NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00427349

  6. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 2 publications
     URL: https://clinicaltrials.gov/study/NCT01010126

  7. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00454363

  8. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 40 - NET condition match; Liver metastases match; Low-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  9. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
     NCT ID: NCT03037385
     Phase: PHASE1 | Status: COMPLETED
     Relevance: 40 - NET condition match; Small intestine NET match; Completed study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT03037385

  10. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 38 - NET condition match; Liver metastases match; Completed PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200


================================================================================

PATIENT 2
----------------------------------------
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Relevant studies found: 10

  1. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 55 - NET condition match; Small intestine NET match; Liver metastases match; Completed PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  2. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
     NCT ID: NCT01524783
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 50 - NET condition match; Small intestine NET match; Completed PHASE3 study; 5 publications
     URL: https://clinicaltrials.gov/study/NCT01524783

  3. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
     NCT ID: NCT01578239
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 47 - NET condition match; Small intestine NET match; Completed PHASE3 study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT01578239

  4. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
     NCT ID: NCT00171873
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 44 - NET condition match; Small intestine NET match; Completed PHASE3 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00171873

  5. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
     NCT ID: NCT00427349
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 44 - NET condition match; Small intestine NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00427349

  6. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; High-grade NET match; Completed PHASE2 study; 2 publications
     URL: https://clinicaltrials.gov/study/NCT01010126

  7. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; High-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00454363

  8. 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
     NCT ID: NCT01563354
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; High-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT01563354

  9. Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
     NCT ID: NCT01253161
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; High-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT01253161

  10. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 40 - NET condition match; Liver metastases match; High-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360


================================================================================

PATIENT 3
----------------------------------------
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.
07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Relevant studies found: 10

  1. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 55 - NET condition match; Small intestine NET match; Liver metastases match; Completed PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  2. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
     NCT ID: NCT01524783
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 50 - NET condition match; Small intestine NET match; Completed PHASE3 study; 5 publications
     URL: https://clinicaltrials.gov/study/NCT01524783

  3. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
     NCT ID: NCT01578239
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 47 - NET condition match; Small intestine NET match; Completed PHASE3 study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT01578239

  4. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
     NCT ID: NCT00171873
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 44 - NET condition match; Small intestine NET match; Completed PHASE3 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00171873

  5. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
     NCT ID: NCT00427349
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 44 - NET condition match; Small intestine NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00427349

  6. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 2 publications
     URL: https://clinicaltrials.gov/study/NCT01010126

  7. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 42 - NET condition match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00454363

  8. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 40 - NET condition match; Liver metastases match; Low-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  9. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
     NCT ID: NCT03037385
     Phase: PHASE1 | Status: COMPLETED
     Relevance: 40 - NET condition match; Small intestine NET match; Completed study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT03037385

  10. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 38 - NET condition match; Liver metastases match; Completed PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200


================================================================================

PATIENT 4
----------------------------------------
Diagnosis: NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)
CT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

08/2015 Start Somatuline
06/2016 DOTATOC PET: Progress der Lebermetastasen, starke Speicherung der Leberläsionen.
Relevant studies found: 10

  1. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 62 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 2 publications
     URL: https://clinicaltrials.gov/study/NCT01010126

  2. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 62 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00454363

  3. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 60 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  4. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 58 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200

  5. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 55 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  6. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
     NCT ID: NCT03375320
     Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING
     Relevance: 53 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Active study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT03375320

  7. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 52 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT02402062

  8. Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
     NCT ID: NCT02420691
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 52 - NET condition match; Pancreatic NET match; Low-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02420691

  9. Pazopanib as Single Agent in Advanced NETs
     NCT ID: NCT01280201
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 52 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT01280201

  10. Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
     NCT ID: NCT00510068
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 50 - NET condition match; Pancreatic NET match; Completed PHASE3 study; 5 publications
     URL: https://clinicaltrials.gov/study/NCT00510068


================================================================================

PATIENT 5
----------------------------------------
Diagnosis: NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)
CT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

06/2015 DOTATOC PET: starke Speicherung der Läsionen.
Relevant studies found: 10

  1. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 62 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 2 publications
     URL: https://clinicaltrials.gov/study/NCT01010126

  2. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 62 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT00454363

  3. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 60 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  4. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 58 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200

  5. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 55 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  6. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
     NCT ID: NCT03375320
     Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING
     Relevance: 53 - NET condition match; Pancreatic NET match; Liver metastases match; Low-grade NET match; Active study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT03375320

  7. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 52 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT02402062

  8. Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
     NCT ID: NCT02420691
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 52 - NET condition match; Pancreatic NET match; Low-grade NET match; Completed PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02420691

  9. Pazopanib as Single Agent in Advanced NETs
     NCT ID: NCT01280201
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 52 - NET condition match; Pancreatic NET match; Liver metastases match; Completed PHASE2 study; 1 publications
     URL: https://clinicaltrials.gov/study/NCT01280201

  10. Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
     NCT ID: NCT00510068
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 50 - NET condition match; Pancreatic NET match; Completed PHASE3 study; 5 publications
     URL: https://clinicaltrials.gov/study/NCT00510068


================================================================================

